The authors concluded that withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with established rheumatoid arthritis increased the risk of flare-up or deterioration. Patients with established rheumatoid arthritis, but adequate symptom control with DMARDs, should normally continue to receive treatment. Although the authors' conclusions reflected the evidence, the limited evidence available means that they should be interpreted with some caution.
Study selection
High quality studies that assessed the effects of withdrawal or titration/reduction of the dose of disease-modifying antirheumatic drugs (DMARDs) in adults with established (disease of over two years duration) rheumatoid arthritis were eligible for inclusion. Studies of non-UK relevant populations were excluded.
The outcome of interest was the total number of patients at the end of the study who experienced disease flares or deleterious effects (clinical deterioration, exacerbation of symptoms).
The included studies were of patients with a disease duration that ranged from 40 months to 16 years (where reported). At baseline, between 60 and 80% of patients were reported to be rheumatoid factor positive (where reported). The mean disease duration ranged from 7.4 to 16 years. Randomised controlled trials compared the effects of withdrawal or dose reduction of azathioprine, penicillamine, methotrexate, intramuscular gold or different DMARDs versus placebo (patients remaining on treatment), or compared varying doses of D-penicillamine. Case series tapered or withdrew infliximab with methotrexate, prednisolone, or methotrexate alone. Study duration ranged from one to 24 months (where reported). The outcomes measured were rheumatoid arthritis flare, clinical deterioration, treatment failure, and changed joint counts.
One reviewer screened studies for inclusion; their appropriateness for addressing the objectives were considered by a clinician.
Assessment of study quality
The quality of randomised controlled trials (RCTs) was assessed according to the National Institute of Health and Clinical Excellence quality assessment criteria, including items on randomisation, allocation concealment, blinding, intention-to-treat analysis, and drop-outs/withdrawals. RCTs demonstrating two or more of the main sources of bias were excluded from the review. It appeared that two reviewers assessed the quality of the trials.
